| Nov 21 |
Zevra Niemann-Pick disease type C drug Miplyffa now available
|
| Nov 21 |
Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C
|
| Nov 16 |
Analysts Have Made A Financial Statement On Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Third-Quarter Report
|
| Nov 14 |
Zevra Therapeutics Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 13 |
Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript
|
| Nov 13 |
Zevra Therapeutics Inc (ZVRA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...
|
| Nov 12 |
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
|
| Nov 12 |
Zevra Therapeutics: Q3 Earnings Snapshot
|
| Nov 12 |
Zevra Therapeutics GAAP EPS of -$0.69 misses by $0.27, revenue of $3.69M misses by $1.17M
|
| Nov 12 |
Zevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates
|
